课题基金 / 基金详情

T cells in HCV/HIV co-infection

T cells in HCV/HIV co-infection
HCV/HIV 共感染中的 T 细胞
批准号:
10318958
负责人:
GEORG Michael LAUER
金额:
$64.85万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-03-01 至 2023-12-31

项目摘要

项目成果

GEORG Michael LAUER的其他基金

相似基金

相关文献

中文摘要
翻译
丙型肝炎病毒(HCV)仍然是一个紧迫的全球威胁,许多国家的新感染率不断上升
英文摘要
Hepatitis C virus (HCV) remains an urgent global threat, with increasing rates of new infections in many jurisdictions due to a resurgence of injection drug use. People who inject drugs (PWID) and MSM are also at risk for HIV infection and when co-infected with these two viruses they suffer from accelerated liver disease progression and lower treatment response rates when interferon-based therapies were used. New interferon- sparing therapies with direct-acting antivirals (DAAs) lead to cure rates of over 95%, even in HCV/HIV coinfected persons. However, there remains an urgent need to protect high-risk populations from chronic HCV infection and re-infection as treatment alone might be insufficient in these populations with often limited access to health care. Prophylactic interventions will require a better understanding of the immune response necessary for protection from chronic infection and how cured subjects can be prevented from re-infection, with special considerations of additional challenges in the context of HIV co-infection and substance use. In this proposal we focus on the impact of HIV co-infection and of drug abuse on the generation and recovery of HCV- specific T cells during primary infection and after therapy. We will utilize PBMC from well-defined cohorts of persons with acute and chronic HCV/HIV co-infection, including longitudinal samples from patients undergoing DAA therapy, together with direct ex-vivo analysis of HCV-specific CD4 and CD8 T cells by flow cytometry and RNAseq of sorted cells on the single cell and population level. Specifically we will define the impact of HIV co-infection on the quality of the critical CD4 T cell response generated during primary HCV infection in HIV positive hosts, will identify the mechanism enabling sustained and functional HCV-specific CD4 responses in patients receiving early DAA treatment, and will determine whether HIV co-infection and substance abuse impair the recovery of HCV-specific T cells after DAA therapy for chronic HCV infection. The results will deliver important insights into the pathogenesis of HCV infection and will inform immunological approaches for the prevention of chronic HCV infection and re-infection in high risk patients with HIV co-infection and/or substance use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HBV-specific T cell immunity in HBV/HIV coinfection
Immune Control and Evadion during Acute HCV Infection
  • 批准号:
    9982171
  • 项目类别:
  • 资助金额:
    $27.6万
  • 财政年份:
    2016
  • 负责人:
    GEORG Michael LAUER
  • 依托单位:
T cell responses at the site of infection
  • 批准号:
    9089889
  • 项目类别:
  • 资助金额:
    $21.75万
  • 财政年份:
    2015
  • 负责人:
    GEORG Michael LAUER
  • 依托单位:
CD4+ T Cells in Acute Versus Chronic HCV Infection
  • 批准号:
    8604683
  • 项目类别:
  • 资助金额:
    $43.5万
  • 财政年份:
    2013
  • 负责人:
    GEORG Michael LAUER
  • 依托单位:
海外基金